Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
303.05
-0.59 (-0.19%)
At close: Jun 5, 2026, 4:00 PM EDT
300.00
-3.05 (-1.01%)
After-hours: Jun 5, 2026, 6:40 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 30 analysts polled by S&P Global, Alnylam Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $445.81. The average 1-year stock price forecast is 47.11% higher than the current stock price, while the lowest is $310 (+2.29%) and the highest is $566 (+86.77%).
Price Target: $445.81 (+47.11%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 15 | 14 | 14 | 15 | 15 |
| Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Hold | 8 | 7 | 8 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 28 | 28 | 28 | 30 | 30 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $510 | Buy | Reiterates | $510 | +68.29% | Jun 4, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $370 | Hold | Maintains | $370 | +22.09% | May 29, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $445 | Buy | Maintains | $445 | +46.84% | May 27, 2026 |
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Buy Maintains $420 | Buy | Maintains | $420 | +38.59% | May 20, 2026 |
| Citi | Citi | Buy Initiates $380 | Buy | Initiates | $380 | +25.39% | May 18, 2026 |
Financial Forecast
Revenue This Year
5.61B
from 3.71B
Increased by 51.09%
Revenue Next Year
7.30B
from 5.61B
Increased by 30.09%
EPS This Year
9.51
from 5.08
Increased by 87.20%
EPS Next Year
13.90
from 9.51
Increased by 46.14%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 6.1B | ||
| Avg | 5.6B | ||
| Low | 5.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 64.7% | ||
| Avg | 51.1% | ||
| Low | 40.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 13.00 | ||
| Avg | 9.51 | ||
| Low | 7.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 155.9% | ||
| Avg | 87.2% | ||
| Low | 56.3% |